This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis
Nature Communications Open Access 15 November 2018
-
Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
Cancer Imaging Open Access 18 April 2018
-
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
BMC Medicine Open Access 12 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dervite I, Hober D, Morel P . Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68–69.
Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
Ng HJ, Lim LC . Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549–552.
Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296–1303.
Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niscola, P., Del Principe, M., Maurillo, L. et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19, 1840–1841 (2005). https://doi.org/10.1038/sj.leu.2403914
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403914
This article is cited by
-
Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
Cancer Imaging (2018)
-
Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis
Nature Communications (2018)
-
Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients
Cellular & Molecular Immunology (2015)
-
Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy
Supportive Care in Cancer (2013)
-
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
BMC Medicine (2011)